A Study of Movement Disorders Using the QMAT At-Home Testing Device
|ClinicalTrials.gov Identifier: NCT01905839|
Recruitment Status : Terminated
First Posted : July 23, 2013
Last Update Posted : July 2, 2017
- Parkinson s disease (PD) affects half a million Americans, causing slow movements, tremors, stiffness, and trouble walking. Currently, these symptoms are measured by physical exam, but this is unreliable and requires an office visit. Researchers want to study a different way to measure PD symptoms, using a home-testing machine called a QMAT device. It can test how quickly someone moves doing different tasks. Researchers will study how this testing compares to physical exam testing and whether the device can detect changes in PD symptoms over time.
- To see if a home testing device can be used to evaluate Parkinson s disease symptoms.
- Adults at least 18 years old with PD.
- Participants will have about 22 clinic visits over 5 years. Each visit will take up to 3 hours. Visits will be scheduled along with visits for another study.
- At visit 1, participants will learn to use the QMAT device and how to send testing information to the clinic by computer. The device has a computer screen, some buttons, and some pegs. Participants will get a device to take home and any accessories.
- Participants will learn 2 QMAT tests. For one, they will press keys as fast as possible. For the other, they will move pegs into holes. The tests will take a total of about 20 minutes.
- Participants will take both tests at home, 2 times on the same day each week, once before their medication, once after.
- A study coordinator will monitor the participant s computer data and discuss the at-home testing at the clinic visits.
|Condition or disease|
|Movement Disorders Parkinson's Disease|
Hide Detailed Description
The purpose of this protocol is to improve the understanding of the pathophysiology of movement disorders and to assess movement in Parkinson s disease by performing small behavioral exercises and objectively measuring movements utilizing the QMAT at home testing device. These devices will be provided by the Kinetics Foundation. We have developed a series of motor tasks that can be performed with the QMAT, a home-based computer module, so that data on patient s movement can be collected frequently and prospectively without obligating the patient to come to a medical center. The study is designed to be observational in nature.
The QMAT device is being implemented to respond to the interest in objectified tests to monitor, analyze, and further understand the physiological aspects of Parkinson s disease. We will conduct:
- Training to patients to perform tasks on the QMAT device and transmit data at home.
- Training to investigators who do not have prior experience using the system
- Testing using the QMAT device that may increase knowledge of a disease process, responsiveness of treatment or be helpful in patient progress evaluations by analyzing data collected from the at home tests.
This protocol includes only non-invasive techniques with minimal risk to the participants. The technique has been piloted as part of the 10-N-0009 protocol, Physiological Investigations in Movement Disorders.
We intend to study patients with diagnosis of Parkinson Disease.
We will enroll up to 60 participants in order to obtain 48 patients who complete the study.
We will assign and train study participants to use the QMAT device at home. This is a portable device with a simple keyboard and pegboard interface, storing data from patient performance at home. There are 2 tasks that are performed using the device. The pegboard task involves transferring pegs from holes on one side of the device to the opposite side of the device. The finger tapping test and the digitography tasks involve having the subject press keys on the keyboard. At enrollment into this study, a time schedule will be discussed with the participant regarding the schedule that these at home tests require to be conducted. We will provide the device, all the components, and a data storage thumb-drive to each participant.
i. Bradykinesia (fine motor movements):
The component of the apparatus that will test fine motor control will involve finger pads that will be tapped in alternating fashion by the patient for 30 seconds.
The primary outcome variable will be mean keystroke velocity (completed alternating cycles/testing period, expressed as cm/sec. Secondary outcomes will be mean frequency expressed as Hz, mean strike duration, expressed as m/sec and temporal variation of the duration of finger strike and frequency (issues of fatigue) expressed as the coefficient of variation (SD/mean). Variation in velocity will be expressed as the SD.
ii. Complex movements: (Pegboard or plugging device):
The At-Home device also contains plugging tasks. Primary outcome: mean movement velocity expressed as seconds per plugging cycle. This measure can be analyzed statistically for all movements to correct for outlier responses and errors. A secondary outcome will also be defatigation (i.e., the linear change of speed during a testing session, expressed as percent of the cycle-time. The variance of speed will be provided by the standard deviation. A regression analysis will allow estimates of the part of the variance that is declared by linear change over the complete task.
|Study Type :||Observational|
|Actual Enrollment :||3 participants|
|Official Title:||A Longitudinal Study Assessing the Pathophysiology of Movement Disorders Utilizing the QMAT at Home Testing Device|
|Study Start Date :||June 18, 2013|
|Actual Primary Completion Date :||April 15, 2015|
|Actual Study Completion Date :||April 15, 2015|
- Mean speed of keystrokes on a repetitive finger movement [ Time Frame: 5 years follow up ]
- Mean speed of movement on a peg movement task [ Time Frame: 5 years follow up ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01905839
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Codrin I Lungu, M.D.||National Institute of Neurological Disorders and Stroke (NINDS)|